The SPARC-1 trial: A phase I study of neoadjuvant combination interleukin-1 beta and PD-1 blockade in localized clear cell renal cell carcinoma.

Matthew Dallos,David H. Aggen,Casey R Ager,Aleksandar Obradović,Clara A Easterlin,Jessica Hawley,Emerson A. Lim,Mark N. Stein,Charles G. Drake

The SPARC-1 trial: A phase I study of neoadjuvant combination interleukin-1 beta and PD-1 blockade in localized clear cell renal cell carcinoma.

2021

Matthew Dallos
David H. Aggen
Casey R Ager
Aleksandar Obradović
Clara A Easterlin
Jessica Hawley
Emerson A. Lim
Mark N. Stein
Charles G. Drake

TPS373Background: Immune checkpoint blockade has significantly improved outcomes for patients with renal cell carcinoma (RCC) in the metastatic setting. However, there is currently no neoadjuvant s...

Keywords:

Blockade
Cancer research
pd 1 blockade
Clear cell renal cell carcinoma
phase i study
Renal cell carcinoma
Immune checkpoint
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations